Standard Biotools INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Long Focus Capital Management, LLC and John Helmers report beneficial ownership of 6.0% of Standard BioTools Inc. common stock as of June 30, 2026.
NASDAQ
Investment firm MAK Capital and Michael A. Kaufman have reported a 6.7% beneficial ownership stake in Standard BioTools Inc.
NASDAQ
Viking Global Investors filed an amended Schedule 13G to reflect the retirement of David C. Ott as a reporting person.
NASDAQ
MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman jointly reported beneficial ownership of 5.19% of Standard BioTools Inc.'s common stock.